Glaxo review could see it sell Ribena and Lucozade
GlaxoSmithKline could sell Lucozade and Ribena after Britain’s biggest pharmaceuticals firm today set out plans for a “strategic review” of the drinks brands.
The drugmaker’s chief executive, Sir Andrew Witty, said he was focused on the “two places where there are cast-iron synergies between pharma and the consumer business, which are over-the-counter medicines, such as Panadol, and emerging markets.
Lucozade and Ribena are iconic brands, but don’t naturally fit into those two places.
Witty said its review, which will be complete by the middle of this year, involved “truly no decisions taken or options ruled out — we could increase investments in certain parts of the world, find a partner, or divest the products.”
The announcement came as GSK suffered from European governments cutting back on healthcare and drugs spending, with annual turnover falling 1% to £26.4 billion in 2012, and pre-tax profits slipping 4% to £7.6 billion.
Total sales in emerging markets now account for just over a quarter of GSK’s business.
- 1 All Blacks Aaron Cruden misses New Zealand flight after drinking session, has brilliant excuse
- 2 Kim Kardashian 'nude photos' leaked on 4chan weeks after Jennifer Lawrence scandal
- 3 'F*ck it, I quit': TV reporter Charlo Greene quits live on air in spectacular fashion
- 4 Alicia Keys leaks nude photo 'to create a kinder and more peaceful world'
- 5 Clothes store Joy angers mental health campaigners with Twitter exchange on bipolar disorders
Scotland could still declare independence – even without referendum, says Alex Salmond
Scottish referendum results: Cross-party consensus collapses amid Tory-Labour spat on the 'English question'
Hilary Mantel 'should be investigated by police' over Margaret Thatcher assassination story, says Lord Bell
Scottish independence: David Cameron is becoming the 'George Bush of Britain'
Plebgate MP Andrew Mitchell called officer a 'little s**t', claim court documents 'exposing ex-Chief Whip's 'record of abusing police'
Archbishop of Canterbury admits doubts about existence of God
iJobs Money & Business
£20000 - £25000 per annum + OTE £40,000: SThree: SThree are a global FTSE 250 ...
£20000 - £25000 per annum + OTE £40000: SThree: As a Recruitment Consultant, y...
£20000 - £25000 per annum + OTE £40,000: SThree: SThree Group have been well e...
Up to £80000: Saxton Leigh: My client, a large commodities broker, is looking ...